Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma
Saved in:
| Published in: | Liver Cancer International |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1867301675809636354 |
|---|---|
| collection | WordPress RSS FRELIP Feed Integration |
| container_title | Liver Cancer International |
| description | |
| discipline_display | Internal Medicine |
| discipline_facet | Internal Medicine |
| format | Online Article RSS Article |
| genre | Journal Article |
| id | rss_article:67938 |
| institution | FRELIP |
| journal_source_facet | Liver Cancer International |
| publishDate | 2026 |
| publishDateSort | 2026 |
| record_format | rss_article |
| spellingShingle | Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma Internal Medicine General Internal Medicine |
| sub_discipline_display | General |
| sub_discipline_facet | General |
| subject_display | Internal Medicine General Internal Medicine Internal Medicine General Internal Medicine |
| subject_facet | Internal Medicine General Internal Medicine |
| title | Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma |
| title_auth | Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma |
| title_full | Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma |
| title_fullStr | Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma |
| title_full_unstemmed | Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma |
| title_short | Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma |
| title_sort | impact of frequent immune‐mediated adverse events on treatment continuity and outcomes during durvalumab plus tremelimumab therapy for unresectable hepatocellular carcinoma |
| topic | Internal Medicine General Internal Medicine |
| url | https://onlinelibrary.wiley.com/doi/10.1002/lci2.70042?af=R |